Apogee therapeutics announces late-breaker presentation of 16-week data from phase 2 apex trial of apg777 for moderate-to-severe atopic dermatitis at the upcoming european academy of dermatology and venereology (eadv) 2025 congress

San francisco and boston, sept. 11, 2025 (globe newswire) -- apogee therapeutics, inc., (nasdaq: apge), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology (i&i) markets, today announced data from the phase 2 apex trial of apg777 for moderate-to-severe atopic dermatitis was accepted for a late-breaker oral presentation at the upcoming eadv congress 2025, to be held in paris, france from september 17-20, 2025. the company will also present multiple poster presentations highlighting apg777's best-in-class potential including data supporting its combination strategy.
APG Ratings Summary
APG Quant Ranking